
Pioneering a disruptive
therapeutic modality
Transformative medicines for
Targeted Protein Stabilization
Our Approach
Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need. We are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drug development by establishing a powerful small-molecule modality for a wide variety of devastating diseases.
The big idea

Targeting a shared mechanism driving disease – protein turnover
The challenge

123-456-7890
Drugging a universal degradation
signal in a target-specific manner
The solution

Find us on Facebook
Establishing an adaptable platform
for restoring protein stability
Reduced protein expression or aberrant protein turnover is a common underlying driver of disease. Genetic mutations can reduce the stability of proteins with essential function; tumor cells often eliminate key regulatory factors to grow unchecked; pathogens co-opt the host ubiquitin-proteasome system (UPS) to modulate immune response. Ubiquitin is a universal tag that marks proteins for destruction and has emerged as a highly sought-after therapeutic target. Although the therapeutic value of augmenting protein stabilization via the UPS has been demonstrated with proteasome inhibitors, these drugs globally inhibit protein degradation in a non-specific manner, limiting their use outside of oncology due to poor tolerability and highlighting the need for targeted approaches.
Our Platform
At Stablix, we are establishing a new paradigm for tackling diverse diseases by harnessing the power of the body’s own cellular machinery. Our RESTORED™ platform generates heterobifunctional small-molecules (RESTORACS™) that selectively recruit active deubiquitinases (DUBs) to target proteins to precisely remove ubiquitin and restore protein function. We are initially leveraging the platform to develop programs to treat rare diseases, cancer and immunological disorders.

Who We Are
Stablix is a New York City-based preclinical stage biotechnology company, pioneering small molecule medicines for targeted protein stabilization. We are an experienced, multi-disciplinary team with a combined power of industry knowledge and creative talent.
Leadership
%20(1).png)
Tony Kingsley
CEO

Kevin Sprott, PhD
COO
Co-Founder

Eddine Saiah, PhD
CSO

Brian Bowman, PhD
SVP of Biology
Co-Founder

Scott Kanner, PhD
Associate Director
Platform Sciences
Co-Founder

Uddhav Shigdel, PhD
Director
Biomolecular Sciences

Yukie Takabatake, PhD
Associate Director
Cellular Biology
Scientific Advisors

Henry Colecraft, PhD
Chair of SAB
Co-Founder

Benedikt Kessler, PhD
University of Oxford
Professor

Chris Dinsmore, PhD
CSO Kronos Bio

Chris Roberts, PhD
Chief Executive Officer
Civetta Therapeutics

Stephen Hale, PhD
Independent Consultant

Andrew Turnbull, PhD
Senior Principal Scientist
CRUK-TDL

Huseyin Mehmet, PhD
Executive Director, New Ventures
UMass Medical School

Mark Saulnier, PhD
Former Research Fellow
Bristol-Myers Squibb

Megan Yao, PhD
Independent Consultant

Jue Chen
William E. Ford Professor Investigator, Howard Hughes Medical Institute; National Academy of Sciences
Board of Directors

Carlo Rizzuto, PhD
Director

Clare Ozawa, PhD
Director

Ali Behbahani, MD
Director
%20(1).png)
Tony Kingsley
Director

Douglas Williams, PhD
Director

J.C. Lopez, MD
Observer

Bihua Chen
Observer

Ezana Demissie
Observer